In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Hold rating on ImmunoGen (NASDAQ: IMGN). The company’s shares closed yesterday at $11.47.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.6% and a 51.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
ImmunoGen has an analyst consensus of Moderate Buy, with a price target consensus of $14.80.
See today’s analyst top recommended stocks >>
Based on ImmunoGen’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $38.61 million. In comparison, last year the company had a GAAP net loss of $17.35 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. Most recently, in March 2018, David Brannon Johnston, the CFO of IMGN sold 10,000 shares for a total of $115,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.
